Company intelligence / Profile preview

Musli Thyropeutics Ltd.

Tzur Moshe, Israelfinder.startupnationcentral.org ↗

Ownership: Private
Development stage: Phase 1

Overview

Musli Thyropeutics developed a novel, patented combination of repurposed small molecule drugs aimed at inducing hypothyroxinemia to slow cancer progression and enhance the efficacy of chemotherapy and radiotherapy. Their lead program targeted glioblastoma with a Phase 2 clinical trial, which was terminated. No active programs or recent clinical results are publicly available[1][3].

Therapeutic areas: OncologyNeurology
Modalities: Small molecules (repurposed drugs)
Industry: Biotech

Partnerships

Abbott Laboratories was listed as an "Active Org." in relation to the drug program[1].

Beyond the preview

Go deeper on Musli Thyropeutics Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Musli Thyropeutics Ltd..

Explore the full profile